Drug Trial Radar · NCT03716115
Therapeutic Approaches to Malnutrition Enteropathy
Last checked: Nov 19, 2026Latest source record: Sep 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
May 4, 2020
Primary completion
Apr 27, 2021
Study completion Apr 27, 2021
Sponsor
- Lead sponsor
- Queen Mary University of LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 59 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The TAME study will evaluate four new approaches which will be compared against the standard care currently in use in the treatment of malnutrition enteropathy in children with severe acute malnutrition. A high pathogen burden causes damage to the intestinal mucosa which exacerbates nutritional impairment and leads to further susceptibility to infection and impaired epithelial regeneration. Enteropathy is characterised by multiple epithelial breaches, microbial translocation from gut lumen to systemic circulation and systemic inflammation.The trial will evaluate the potential impact of four interventions (colostrum, N-acetyl glucosamine, teduglutide, and budesonide) given for 14 days, which aim at mucosal restoration. The trial will determine if repairing damage to the small intestinal mucosa leads to the reduction of systemic inflammation and thus lessening the nutritional impairment, and so if this contributes to the reduction of mortality in children. In Zambia only, endoscopic biopsies and confocal laser endomicroscopy will be used to evaluate response and confirm safety at a mucosal level. Identifying an agent or agents which contribute most to mucosal healing will then ultimately lead to further large phase 3 trial in which the agent(s) will be further evaluated. The trial also anticipates to gain a more in depth understanding of pathophysiology and may identify where current management strategies of treating malnutrition enteropathy in children are failing.
Conditions
- Severe Acute Malnutrition
Interventions
Colostrum high protein powder (Neovite)Dietary supplement
Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.
N-Acetyl Glucosamine (GInNAC)Drug
N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
TeduglutideDrug
Teduglutide will be administered daily as subcutaneous injection
BudesonideDrug
Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite measure of concentration of three faecal inflammatory markersTime frame: 14-18 days
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University Teaching Hospital, Nationalist Road
Lusaka, Zambia
Harare Central Hospital
Harare, Zimbabwe
Parirenyatwa Hospital
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.